Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6P589
UPID:
TP8L2_HUMAN
Alternative names:
Inflammation factor protein 20
Alternative UPACC:
Q6P589; Q6I9Y0; Q9H2H7; Q9H5G2
Background:
Tumor necrosis factor alpha-induced protein 8-like protein 2, also known as Inflammation factor protein 20, plays a crucial role in regulating the immune system. It acts as a negative regulator of both innate and adaptive immunity, ensuring immune homeostasis. This protein inhibits key pathways such as Toll-like receptor and T-cell receptor function, JUN/AP1, and NF-kappa-B activation, and promotes Fas-induced apoptosis.
Therapeutic significance:
Understanding the role of Tumor necrosis factor alpha-induced protein 8-like protein 2 could open doors to potential therapeutic strategies. Its ability to maintain immune balance and prevent hyperresponsiveness highlights its potential as a target in treating immune-related disorders.